The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Olopatadine is combined with Benzydamine. The serum concentration of Simvastatin can be increased when it is combined with Perindopril. Ramipril may increase the hypotensive activities of Vincamine. Bisoprolol may increase the hypotensive activities of Pentolinium. The risk or severity of adverse effects can be increased when Sacubitril is combined with Tolmetin. The therapeutic efficacy of Sultamicillin can be decreased when used in combination with Demeclocycline. The metabolism of Fenofibrate can be decreased when combined with Diltiazem. The serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir. The metabolism of Clomipramine can be decreased when combined with Lidocaine. The risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclizine. The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Trandolapril. The risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone. Carbaspirin calcium may increase the anticoagulant activities of Enoxaparin. The serum concentration of Saxagliptin can be decreased when it is combined with Clotrimazole. The risk or severity of adverse effects can be increased when Ergonovine is combined with Prednisolone. Candoxatril may increase the arrhythmogenic activities of Ciprofloxacin. Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rosoxacin. Difluprednate may increase the hypokalemic activities of Metolazone. Nalidixic Acid may increase the hypoglycemic activities of Sitagliptin. The risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril. Felodipine may increase the hypotensive activities of Metyrosine. Isocarboxazid may increase the hypotensive activities of Indapamide. Ergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol. The metabolism of Mefloquine can be decreased when combined with Imatinib. The serum concentration of Elvitegravir can be increased when it is combined with Fusidic Acid. Mephedrone may increase the analgesic activities of Buprenorphine. The risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz. Remikiren may increase the hypotensive activities of Phentolamine. The metabolism of Triamcinolone can be decreased when combined with Clarithromycin. The risk or severity of adverse effects can be increased when Amperozide is combined with Cyclizine. The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bumetanide. The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone. Pindolol may increase the hypotensive activities of Obinutuzumab. The therapeutic efficacy of Glyburide can be decreased when used in combination with Drospirenone. The risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam. The risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone. The serum concentration of Dronabinol can be increased when it is combined with Tolbutamide. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab. Diethylstilbestrol may decrease the anticoagulant activities of Protein C. The risk or severity of adverse effects can be increased when Etorphine is combined with Pargyline. The therapeutic efficacy of Everolimus can be decreased when used in combination with Sarilumab. The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol. Pentobarbital may increase the hypotensive activities of Papaverine. The risk or severity of adverse effects can be increased when Methohexital is combined with Tiagabine. The risk or severity of adverse effects can be increased when Methohexital is combined with Benzocaine. Mebanazine may increase the hypoglycemic activities of Saxagliptin. The serum concentration of Rifaximin can be increased when it is combined with Rilpivirine. The risk or severity of adverse effects can be increased when Metolazone is combined with Canagliflozin. The risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac. The metabolism of Ondansetron can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Candesartan is combined with Temocapril. The metabolism of Repaglinide can be decreased when combined with Pioglitazone. Ibuprofen may increase the nephrotoxic activities of Olsalazine. The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetracaine. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Bromperidol. The risk or severity of adverse effects can be increased when Oxycodone is combined with Proparacaine. Fospropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydroxyprogesterone caproate. The metabolism of Bupropion can be decreased when combined with Sulfadiazine. Aminosalicylic Acid may decrease the antihypertensive activities of Quinapril. The serum concentration of Colchicine can be increased when it is combined with Scopolamine. The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate. The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilenin. The serum concentration of Vilanterol can be increased when it is combined with Ivacaftor. The metabolism of Calcitriol can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclofenac. Carbaspirin calcium may increase the hypoglycemic activities of Glyburide. The metabolism of Dapagliflozin can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Eprosartan is combined with Hydrochlorothiazide. The serum concentration of Aminophylline can be decreased when it is combined with Secobarbital. The metabolism of Voxilaprevir can be decreased when combined with Pioglitazone. Fleroxacin may increase the hypoglycemic activities of Dapagliflozin. The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide. The risk or severity of adverse effects can be increased when Tamsulosin is combined with Mannitol. The metabolism of Enasidenib can be decreased when combined with Sulfadiazine. The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluprednate. The metabolism of Timolol can be decreased when combined with Tranylcypromine. The serum concentration of Hydroflumethiazide can be increased when it is combined with Propiverine. Aloxiprin may increase the anticoagulant activities of Certoparin. The serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib. The serum concentration of Estazolam can be increased when it is combined with Darunavir. The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid. The metabolism of Ketobemidone can be decreased when combined with Pioglitazone. The therapeutic efficacy of Ticarcillin can be decreased when used in combination with Minocycline. Disopyramide may increase the bradycardic activities of Timolol. The serum concentration of Fentanyl can be decreased when it is combined with Siltuximab. The serum concentration of Delavirdine can be decreased when it is combined with Simeprevir. The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indomethacin. The risk or severity of adverse effects can be increased when Halothane is combined with Lercanidipine. The risk or severity of adverse effects can be increased when Chloroquine is combined with Budesonide. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine. Nebivolol may increase the orthostatic hypotensive activities of Tamsulosin. The serum concentration of Tamsulosin can be increased when it is combined with Netupitant. The serum concentration of Flumethasone can be increased when it is combined with Lopinavir. The risk or severity of adverse effects can be increased when Ergonovine is combined with Levofloxacin. The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bufexamac. The serum concentration of Levonorgestrel can be decreased when it is combined with Prucalopride. The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ramelteon. The risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine. The risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amdinocillin. Scopolamine may increase the sedative activities of Ropinirole. The serum concentration of Levothyroxine can be increased when it is combined with Simeprevir. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisone. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Methocarbamol. Ipratropium bromide may increase the anticholinergic activities of Aclidinium. The risk or severity of adverse effects can be increased when Ramipril is combined with Cilazapril. The metabolism of Miconazole can be decreased when combined with Sulfisoxazole. The therapeutic efficacy of Dextran can be decreased when used in combination with Desogestrel. Meclofenamic acid may decrease the antihypertensive activities of Hydralazine. The risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol. The metabolism of Ketamine can be decreased when combined with Rosiglitazone. Buprenorphine may increase the serotonergic activities of Etoperidone. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone. Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin. Sertraline may increase the hyponatremic activities of Methyclothiazide. The serum concentration of Conjugated estrogens can be decreased when it is combined with Quinapril. The risk or severity of adverse effects can be increased when Fosinopril is combined with Sacubitril. The serum concentration of Afatinib can be increased when it is combined with Ciprofloxacin. The serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib. The risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram. Azelastine may decrease the antihypertensive activities of Bevantolol. The serum concentration of Benzyl alcohol can be increased when it is combined with Ivacaftor. The metabolism of Dapsone can be decreased when combined with Esomeprazole. Penbutolol may increase the hypoglycemic activities of Acetohexamide. The risk or severity of adverse effects can be increased when Heroin is combined with Potassium.